[Corrigendum] lncRNA HAR1B has potential to be a predictive marker for pazopanib therapy in patients with sarcoma

• Authors:
  • Hideharu Yamada
  • Masanobu Takahashi
  • Munenori Watanuki
  • Mika Watanabe
  • Sakura Hiraide
  • Ken Saijo
  • Keigo Komine
  • Chikashi Ishioka

• View Affiliations

  
  Affiliations: Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Miyagi 980‑8575, Japan, Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Miyagi 980‑8575, Japan, Department of Orthopaedic Surgery, Tohoku University Graduate School of Medicine, Sendai, Miyagi 980‑8575, Japan, Department of Pathology, Tohoku University Hospital, Sendai, Miyagi 980‑8574, Japan
• Published online on: August 2, 2021     https://doi.org/10.3892/ol.2021.12959
• Article Number: 698

• Copyright : © Yamada et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Article